Juniper Pharmaceuticals (JNP) 10-Q 2 May 14 2014 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Mar. 31, 2014	Apr. 29, 2014
Document And Entity Information [Abstract]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	31-Mar-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q1	'
Entity Registrant Name	'COLUMBIA LABORATORIES INC	'
Entity Central Index Key	'0000821995	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Non-accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	10,758,505

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$12,243	$20,715
Accounts receivable, net	7,258	7,197
Amounts due from related parties	'	900
Inventories	2,405	2,584
Prepaid expenses and other current assets	1,259	831
Total current assets	23,165	32,227
Property and equipment, net	13,785	13,226
Intangible assets, net	2,758	2,828
Goodwill	11,251	11,152
Deferred tax assets	563	570
Other assets	91	89
Total assets	51,613	60,092
Current liabilities:	'	'
Accounts payable	3,190	2,805
Accrued expenses	1,890	2,488
Deferred revenue	637	754
Notes payable	254	250
Total current liabilities	5,971	6,297
Deferred revenue, net of current portion	2,130	2,243
Notes payable, net of current portion	3,719	3,745
Common stock warrant liability	70	379
Total liabilities	11,890	12,664
Commitments and contingencies	'	'
Contingently redeemable series C preferred stock, 0.55 shares issued and outstanding (liquidation preference of $550)	550	550
Shareholders' equity:	'	'
Preferred stock, value	'	'
Common stock $.01 par value; 150,000 shares authorized; 12,159 issued and 10,759 outstanding at March 31, 2014 and 12,152 shares issued and outstanding at December 31, 2013	122	122
Additional paid-in capital	287,217	287,048
Treasury stock (at cost), 1,400 shares at March 31, 2014	-8,509	'
Accumulated deficit	-241,233	-241,662
Accumulated other comprehensive income	1,576	1,370
Total shareholders' equity	39,173	46,878
Total liabilities and shareholders' equity	51,613	60,092
Series B Convertible Preferred Stock [Member]	'	'
Shareholders' equity:	'	'
Preferred stock, value	'	'

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, except Share data, unless otherwise specified
Preferred stock, par value	$0.01	$0.01
Preferred stock, shares authorized	1,000,000	1,000,000
Common stock, par value	$0.01	$0.01
Common stock, shares authorized	150,000,000	150,000,000
Common stock, shares issued	12,159,000	12,152,000
Common stock, shares outstanding	10,759,000	12,152,000
Purchase of treasury shares	1,400,000	'
Redeemable Series C Preferred Stock [Member]	'	'
Preferred stock, shares issued	550	550
Preferred stock, shares outstanding	550	550
Preferred stock, liquidation preference, value	$550	$550
Series B Convertible Preferred Stock [Member]	'	'
Preferred stock, shares issued	130	130
Preferred stock, shares outstanding	130	130
Preferred stock, liquidation preference, value	$13	$13

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Revenues	'	'
Product revenues	$3,294	$5,373
Product revenues from related party	167	'
Service revenues	2,710	'
Royalties	363	86
Royalties from related party	714	800
Other revenues	'	57
Total revenues	7,248	6,316
Cost of product revenues	2,426	2,842
Cost of service revenues	1,846	'
Total cost of revenues	4,272	2,842
Gross profit	2,976	3,474
Operating expenses	'	'
Sales and marketing	401	'
Acquisition related expenses	'	483
General and administrative	2,451	1,978
Total operating expenses	2,852	2,461
Income from operations	124	1,013
Interest (expense) income, net	-34	53
Change in fair value of common stock warrant liability	309	205
Other income (expense), net	42	-26
Total non-operating income	317	232
Income before income taxes	441	1,245
Provision for income taxes	12	3
Net income	$429	$1,242
Basic net income per common share	$0.04	$0.11
Diluted net income per common share	$0.01	$0.09
Basic weighted average common shares outstanding	11,739	10,916
Diluted weighted average common shares outstanding	11,764	11,073

Consolidated_Statements_of_Com

Consolidated Statements of Comprehensive Income (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Statement Of Income And Comprehensive Income [Abstract]	'	'
Net income	$429	$1,242
Other comprehensive income (loss) components:	'	'
Foreign currency translation	206	-5
Unrealized loss on short-term investments	'	-9
Total other comprehensive income (loss)	206	-14
Comprehensive income	$635	$1,228

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Operating activities:	'	'
Net income	$429	$1,242
Reconciliation of net income to net cash provided by operating activities:	'	'
Depreciation and amortization	448	108
Change in fair value of common stock warrant liability	-309	-205
Stock-based compensation expense	164	106
Deferred income taxes	7	'
Gain on disposal of fixed assets	'	-4
Changes in operating assets and liabilities:	'	'
Accounts receivable	-17	-1,618
Due from related party	900	1,379
Inventories	178	387
Prepaid expenses and other current assets	-428	282
Other non-current assets	-2	-114
Accounts payable	373	-28
Accrued expenses	-605	-761
Deferred revenue	-254	-65
Net cash provided by operating activities	884	709
Investing activities:	'	'
Purchases of property and equipment	-799	-13
Additions to short-term investments	'	-52
Net cash used in investing activities	-799	-65
Financing activities:	'	'
Proceeds from exercise of common stock options	12	0
Purchase of treasury stock	-8,509	'
Principal payments on notes payable	-58	'
Dividends paid	-7	-7
Net cash used in financing activities	-8,562	-7
Effect of exchange rate changes on cash and cash equivalents	5	-70
Net (decrease) increase in cash and cash equivalents	-8,472	567
Cash and cash equivalents, beginning of period	20,715	13,204
Cash and cash equivalents, end of period	12,243	13,771
Supplemental cash flow information	'	'
Cash paid for interest	34	'
Cash paid for income taxes	$3	$3

Interim_Consolidated_Financial

Interim Consolidated Financial Statements	3 Months Ended
	Mar. 31, 2014
Accounting Policies [Abstract]	'
Interim Consolidated Financial Statements	'
	(1) Interim Consolidated Financial Statements
	The accompanying unaudited interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim information and pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) for reporting on Form 10-Q. Accordingly, certain information and footnote disclosures required for complete financial statements are not included herein. It is recommended that these financial statements be read in conjunction with the consolidated financial statements and related notes that appear in the Annual Report on Form 10-K of Columbia Laboratories, Inc. (“Columbia”) for the year ended December 31, 2013 filed with the SEC on March 5, 2014. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) necessary for the fair presentation of the consolidated financial information for the interim periods reported have been made. Results of operations for the three months ended March 31, 2014 are not necessarily indicative of the results for the year ending December 31, 2014 or any period thereafter.
	Reclassifications
	For comparability purposes, certain prior period amounts in the consolidated financial statements have been reclassified to conform to the current period’s presentation within the consolidated statements of operations and consolidated statements of cash flows.
	Basis of Presentation
	On July 26, 2013, Columbia’s Board of Directors set a ratio of 1-for-8 for its previously approved reverse stock split which took effect on August 9, 2013. The reverse stock split was approved by Columbia’s shareholders at its annual meeting of shareholders on May 1, 2013. All share and per share amounts relating to the common stock, stock options and warrants included in the interim consolidated financial information and accompanying footnotes have been retroactively adjusted for all periods presented to give effect to this reverse stock split, including reclassifying an equal amount to the reduction in par value of common stock to additional paid-in capital. The reverse stock split did not result in a retroactive adjustment to the share amounts for any of the classes of the Company’s preferred stock.
	Management Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosures at the date of the financial statements during the reporting period. Significant estimates are used for, but are not limited to revenue recognition, sales return reserves, allowance for doubtful accounts, inventory reserve, impairment analysis of goodwill and intangibles including their useful lives, deferred tax assets, liabilities and valuation allowances, common stock warrant valuations, and fair value of stock options. On an ongoing basis, management evaluates its estimates. Actual results could differ from those estimates.

Inventories

Inventories	3 Months Ended
	Mar. 31, 2014
Inventory Disclosure [Abstract]	'
Inventories	'
	(2) Inventories
	Inventories are stated at the lower of cost (first-in, first-out) or market. Components of inventory cost include materials, labor and manufacturing overhead. Inventories consist of the following (in thousands):
		March 31,		December 31,
		2014		2013
	Raw materials	$	480	$	771
	Work in process		1,273		775
	Finished goods		652		1,038
	Total	$	2,405	$	2,584

Goodwill_and_Intangible_Assets

Goodwill and Intangible Assets	3 Months Ended
	Mar. 31, 2014
Goodwill And Intangible Assets Disclosure [Abstract]	'
Goodwill and Intangible Assets	'
	(3) Goodwill and Intangible Assets
	Changes to goodwill during the three months ended March 31, 2014 were as follows (in thousands):
		Total
	Balance – December 31, 2013	$	11,152
	Effects of foreign currency translation		99
	Balance – March 31, 2014	$	11,251
	Intangible assets consist of the following at March 31, 2014 and December 31, 2013 (in thousands):
		Trademark			Developed			Customer			Total
					Technology			Relationships
	Gross carrying amount—March 31, 2014	$	300		$	1,370		$	1,240		$	2,910
	Translation adjustment		16			76			69			161
	Accumulated amortization		(57	)		(155	)		(101	)		(313	)
	Balance—March 31, 2014	$	259		$	1,291		$	1,208		$	2,758
		Trademark			Developed			Customer			Total
					Technology			Relationships
	Gross carrying amount—December 31, 2013	$	300		$	1,370		$	1,240		$	2,910
	Translation adjustment		13			62			56			131
	Accumulated amortization		(36	)		(91	)		(86	)		(213	)
	Balance—December 31, 2013	$	277		$	1,341		$	1,210		$	2,828
	Amortization expense related to the developed technology is classified as a component of cost of service revenues in the accompanying consolidated statements of operations. Amortization expense related to trademark and customer relationships is classified as a component of general and administrative expenses in the accompanying consolidated statements of operations.
	Amortization expense for the three months ended March 31, 2014, was $0.1 million. There was no amortization expense for the three months ended March 31, 2013. As of March 31, 2014, amortization expense on existing intangible assets for the next five years and beyond is as follows (in thousands):
	Year ending December 31,	Total
	Remainder of 2014	$	421
	2015		540
	2016		490
	2017		389
	2018		357
	2019 and thereafter		561
	Total	$	2,758

Debt_and_Other_Contractual_Obl

Debt and Other Contractual Obligations	3 Months Ended
	Mar. 31, 2014
Text Block [Abstract]	'
Debt and Other Contractual Obligations	'
	(4) Debt and other Contractual Obligations
	In September 2013, Columbia assumed debt of $3.9 million in connection with its acquisition of Molecular Profiles. Molecular Profiles had entered into a Business Loan Agreement (“Loan Agreement”) to fund the construction and completion of a second facility, which includes analytical labs, office space, and a manufacturing facility in the United Kingdom, covering three loan facilities with Lloyds TSB Bank (“Lloyds”), as administrative agent. Prior to the acquisition, Molecular Profiles had drawn down $3.9 million under the loan facilities and as of March 31, 2014 owes $4.0 million under the Loan Agreement due to foreign currency revaluation. The three loan facilities are each repayable in monthly installments, beginning in February 2013 for one of the facilities and in October 2013 for the other two facilities. Repayment under all three facilities are payable over a 15 year period from the date of drawdown. Two of the facilities bear interest at the Bank of England’s base rate plus 1.95% and 2.55%, respectively. The interest rate at March 31, 2014 for these two facilities was 2.45% and 3.05%, respectively. The third facility is a fixed rate agreement bearing interest at 3.52% per annum. The weighted average interest rate for the three loan facilities for the three months ended March 31, 2014 was 3.00%. Borrowings under the Loan Agreement are secured by the mortgaged property and an unlimited lien on other assets of Molecular Profiles. The Loan Agreement contains financial covenants that limit the amount of indebtedness the Company may incur, requires the Company to maintain certain levels of net worth, and restricts the Company’s ability to materially alter the character of its business. The Company remains in compliance with all of the covenants under the Loan Agreement.
	Columbia assumed a $2.5 million obligation under a grant arrangement with the Regional Growth Fund on behalf of the Secretary of State for Business, Innovation, and Skills in the United Kingdom. Molecular Profiles used this grant to fund the construction of its second facility. As a part of the arrangement, the Company is required to create and maintain certain full-time equivalent personnel levels through October 2017. As of March 31, 2014, the Company remains in compliance with the covenants of the arrangement.
	The Regional Growth Fund obligation is recognized in the other income net line item in the consolidated statement of operations and is recognized on a decelerated basis over the obligation period through October 2017. As of March 31, 2014, the obligation is valued at $2.5 million due to foreign currency revaluation and is recorded as deferred revenue on the consolidated balance sheets. The amount of other income on the obligation that will be recognized provided the Company remains in compliance with the covenants will be the following (in thousands):
	Year	Total
	Remainder of 2014	$	266
	2015		599
	2016		865
	2017		799
	Total	$	2,529

Geographic_Information_and_Con

Geographic Information and Concentrations	3 Months Ended
	Mar. 31, 2014
Text Block [Abstract]	'
Geographic Information and Concentrations	'
	(5) Geographic Information and Concentrations
	The Company and its subsidiaries are engaged in one line of business: providing pharmaceutical development, clinical trial manufacturing, and advanced analytical and consulting services to the pharmaceutical industry and the manufacture and supply of CRINONE® (progesterone gel) to its licensee, Merck Serono. The Company has consolidated and runs all of its operational functions in one location in Nottingham, United Kingdom. The Company owns certain plant and equipment physically located at third party contractor facilities in the United Kingdom and Switzerland. The Company’s largest customer, Merck Serono, utilizes a Switzerland-based subsidiary to acquire product from us, which it then sells throughout the world excluding the U.S.
	The following tables show selected information by geographic area (in thousands):
	Revenues:
		Three Months Ended
		March 31,
		2014		2013
	United States	$	2,501	$	918
	Switzerland		3,531		5,373
	Other countries		1,216		25
	Total	$	7,248	$	6,316
	Total assets:
		March 31,		December 31,
		2014		2013
	United States	$	12,766	$	20,278
	Switzerland		1,728		3,063
	United Kingdom		36,942		36,487
	Other countries		177		264
	Total	$	51,613	$	60,092
	Long-lived assets:
		March 31,		December 31,
		2014		2013
	United States	$	289	$	306
	Switzerland		28		22
	United Kingdom		13,557		12,987
	Other countries		2		—
	Total	$	13,876	$	13,315
	No other individual country represented greater than 10% of total revenues, total assets, or total long-lived assets for any period presented.
	For the three months ended March 31, 2014, Merck Serono and Actavis accounted for 45% and 16% of net revenues, respectively. For the three months ended March 31, 2013, Merck Serono and Actavis accounted for 85% and 13% of net revenues, respectively. No additional customers accounted for 10% or more of total revenues for the three months ended March 31, 2014 and 2013.

Property_and_Equipment

Property and Equipment	3 Months Ended
	Mar. 31, 2014
Property Plant And Equipment [Abstract]	'
Property and Equipment	'
	(6) Property and Equipment
	Property and equipment consists of the following:
		Estimated	March 31, 2014			December 31, 2013
		Useful Life	Cost			Cost
		(Years)
	Machinery and equipment	10-Mar	$	4,543		$	4,288
	Furniture and fixtures	5-Mar		1,010			1,010
	Computer equipment and software	3		184			183
	Buildings and leasehold improvements	Up to 39		9,701			9,616
	Land	Indefinite		632			627
	Construction in-process			673			104
				16,743			15,828
	Less: Accumulated depreciation			(2,958	)		(2,602	)
	Total		$	13,785		$	13,226
	Depreciation expense for the three months ended March 31, 2014 was $0.4 million. Depreciation expense for the three months ended March 31, 2013 was $0.1 million.

Sales_Returns_Reserves

Sales Returns Reserves	3 Months Ended
	Mar. 31, 2014
Text Block [Abstract]	'
Sales Returns Reserves	'
	(7) Sales Returns Reserves
	Except for sales to licensees, Columbia’s return policy allows product to be returned for a period beginning three months prior to the product expiration date and ending twelve months after the product expiration date. Products sold to Merck Serono and Actavis are not returnable to Columbia nor is Columbia responsible for returns to Merck Serono on international product sales. Columbia is only responsible for sales returns for CRINONE and PROCHIEVE products sold to domestic customers prior to the Actavis, Inc. (“Actavis”) transaction in July 2010, and for STRAINT sold prior to the sale of STRIANT® (testosterone buccal system) to Auxilium Pharmaceuticals LLC (“Auxilium”) in April 2011. Provisions for returns on sales to wholesalers, distributors and retail chain stores were estimated based on a percentage of sales, using such factors as historical sales information, distributor inventory levels and product prescription data, and were recorded as a reduction to sales in the same period as the related sales were recognized. Columbia evaluates its remaining provision for returns on a quarterly basis based on the rate of returns processed and adjusts the provision as necessary.
	An analysis of the reserve for sales returns at March 31, 2014 is as follows (in thousands):
		Total
	Balance — December 31, 2013	$	138
	Provision:
	Related to current period sales		—
	Related to prior period sales		—
			138
	Returns:
	Related to current period sales		—
	Related to prior period sales		(2	)
			(2	)
	Balance — March 31, 2014	$	136

Net_Income_Per_Common_Share

Net Income Per Common Share	3 Months Ended
	Mar. 31, 2014
Earnings Per Share [Abstract]	'
Net Income Per Common Share	'
	(8) Net Income Per Common Share
	The calculation of basic and diluted income per common and common equivalent share is as follows (in thousands except for per share data):
		Three Months Ended
		March 31,
		2014			2013
	Basic net income per common share
	Net income	$	429		$	1,242
	Less: Preferred stock dividends		(7	)		(7	)
	Net income applicable to common stock	$	422		$	1,235
	Basic weighted average number of common shares outstanding		11,739			10,916
	Basic net income per common share	$	0.04		$	0.11
	Diluted net income per common share
	Net income applicable to common stock	$	422		$	1,235
	Add: Preferred stock dividends		7			7
	Less: Fair value of stock warrants for dilutive warrants		(309	)		(205	)
	Net income applicable to dilutive common stock	$	120		$	1,037
	Basic weighted average number of common shares outstanding		11,739			10,916
	Effect of dilutive securities
	Dilutive stock awards		25			15
	Dilutive preferred share conversions		—			142
			25			157
	Diluted weighted average number of common shares outstanding		11,764			11,073
	Diluted net income per common share	$	0.01		$	0.09
	Basic income per common share is computed by dividing the net income, less preferred dividends by the weighted-average number of shares of common stock outstanding during a period. The diluted earnings per common share calculation gives effect to dilutive options, warrants, convertible notes, convertible preferred stock, and other potential dilutive common stock including selected restricted shares of common stock outstanding during the period. Diluted income per share is based on the treasury stock method and includes the effect from potential issuance of common stock, such as shares issuable pursuant to the exercise of stock options, assuming the exercise of all in-the-money stock options. Common share equivalents have been excluded where their inclusion would be anti-dilutive.
	Shares to be issued upon the exercise of the outstanding options and warrants, convertible preferred stock and selected restricted shares of common stock excluded from the income per share calculation amounted to 1.8 million in each of the three month periods ended March 31, 2014 and 2013, because the awards were anti-dilutive.

Accumulated_Other_Comprehensiv

Accumulated Other Comprehensive Income	3 Months Ended
	Mar. 31, 2014
Equity [Abstract]	'
Accumulated Other Comprehensive Income	'
	(9) Accumulated Other Comprehensive Income
	Changes to accumulated other comprehensive income during the three months ended March 31, 2014 were as follows (in thousands):
		Translation		Accumulated Other
		Adjustment		Comprehensive
				Income
	Balance – December 31, 2013	$	1,370	$	1,370
	Current period other comprehensive income		206		206
	Balance – March 31, 2014	$	1,576	$	1,576

StockBased_Compensation

Stock-Based Compensation	3 Months Ended
	Mar. 31, 2014
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Stock-Based Compensation	'
	(10) Stock-Based Compensation
	Columbia recorded stock-based compensation expense of $0.2 million and $0.1 million for the three months ended March 31, 2014 and 2013, respectively.
	Total stock-based compensation expense was recorded to operating expenses based upon the functional responsibilities of the individuals holding the respective options as follows (in thousands):
		Three Months Ended
		March 31,
		2014			2013
	Sales and marketing	$	3		$	—
	General and administrative		161			106
	Total stock-based compensation	$	164		$	106
	Cash received from option exercises was $12,000 during the three months ended March 31, 2014. There were no option exercises in the three months ended March 31, 2013.
	Columbia granted 222,000 and 88,750 stock options during the three months ended March 31, 2014 and 2013, respectively.
	The Company uses the Black-Scholes option pricing model to determine the estimated grant date fair values for stock-based awards. The weighted-average grant date fair values of the options granted during the three months ended March 31, 2014 and 2013 were $4.51 and $3.52, respectively, using the following assumptions:
		Three Months Ended
		March 31,
		2014		2013
	Risk free interest rate	1.64%		0.71%-0.76%
	Expected term	4.75 years		4.75 years
	Dividend yield	—		—
	Expected volatility	81.36%		96.52%-97.02%
	Option-pricing models require the input of various subjective assumptions, including the option’s expected life and the price volatility of the underlying stock. Columbia’s estimated expected stock price volatility is based on its own historical volatility. Columbia’s expected term of options granted during the three months ended March 31, 2014 and 2013 was derived using the simplified method. The risk-free rate for the expected term of the option is based on the U.S. Treasury yield curve in effect at the time of grant.
	As of March 31, 2014, the total unrecognized compensation cost related to outstanding stock options and RSAs expected to vest was $1.2 million, which the Company expects to recognize over a weighted-average period of 3.58 years.

Legal_Proceedings

Legal Proceedings	3 Months Ended
	Mar. 31, 2014
Commitments And Contingencies Disclosure [Abstract]	'
Legal Proceedings	'
	(11) Legal Proceedings
	Claims and lawsuits are filed against the Company from time to time. Although the results of pending claims are always uncertain, the Company believes that it has adequate reserves or adequate insurance coverage in respect of these claims, but no assurance can be given as to the sufficiency of such reserves or insurance coverage in the event of any unfavorable outcome resulting from these actions.
	Between February 1, 2012 and February 6, 2012, two putative securities class action complaints were filed against Columbia and certain of its officers and directors in the United States District Court for the District of New Jersey. These actions were filed under the captions Wright v. Columbia Laboratories, Inc., et al., and Shu v. Columbia Laboratories, Inc., et al and asserted claims under sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5 promulgated under the Exchange Act on behalf of an alleged class of purchasers of the common stock during the period from December 6, 2010 through January 20, 2012. Both actions were consolidated into a single proceeding entitled In re Columbia Laboratories, Inc., Securities Litigation, under which Actavis, Inc., and three of its officers have been added as defendants. The Consolidated Amended Complaint alleged that Columbia and two of its officers, one of whom is a director, omitted to state material facts that they were under a duty to disclose, and made materially false and misleading statements that related to the results of Columbia’s PREGNANT study and the likelihood of approval by the U.S. Food and Drug Administration (“FDA”) of a New Drug Application (“NDA”) to market progesterone vaginal gel 8% for the prevention of preterm birth in women with premature cervical shortening. According to the amended complaint, these alleged omissions and misleading statements had the effect of artificially inflating the market price of the common stock. The plaintiffs sought unspecified damages on behalf of the putative class and an award of costs and expenses, including attorney’s fees. On June 11, 2013, the Court dismissed the amended complaint for failure to state a claim upon which relief could be granted, holding that the plaintiffs did not adequately plead facts supporting an inference of an intent to deceive investors. The Court permitted the plaintiffs to file a second amended complaint, and they did so on July 11, 2013. Columbia moved to dismiss the second amended complaint. On October 21, 2013, the Court dismissed the second amended complaint. The Court ruled that changes the plaintiffs made to their first amended complaint “still do not create a strong inference that the Defendants acted with an intent to deceive, manipulate or defraud.” The Court ordered that if the plaintiffs sought to attempt to plead a cognizable action in a third amended complaint, they must do so within thirty days and specifically address why the attempt would not be futile. The plaintiffs chose not to file any further amendments and the case was dismissed with prejudice on December 2, 2013. On December 20, 2013, the plaintiffs appealed the dismissal to the United States Court of Appeals for the Third Circuit. The Third Circuit will consider the matter after briefing is completed. Columbia believes that the appealed action is without merit, and intends to defend it vigorously. At this time, it is not possible to determine the likely outcome of, or to estimate the potential liability related to this action, and Columbia has not made any provision for losses in connection with it.

Fair_Value_of_Financial_Instru

Fair Value of Financial Instruments	3 Months Ended
	Mar. 31, 2014
Fair Value Disclosures [Abstract]	'
Fair Value of Financial Instruments	'
	(12) Fair Value of Financial Instruments
	U.S. GAAP establishes a framework for measuring fair value under generally accepted accounting principles and enhances disclosures about fair value measurements. Fair value is defined as the amount that would be received for an asset or paid to transfer a liability (i.e., an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value maximize the use of observable inputs and minimize the use of unobservable inputs. The standard describes the following fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value:
	Level 1: Quoted prices in active markets for identical assets and liabilities.
	Level 2: Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
	Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
	The fair value of cash and cash equivalents are classified as level 1 at March 31, 2014 and December 31, 2013.
	The estimated fair value of the common stock warrant liability resulting from the October 2009 registered direct offering of 1,362,500 shares of the common stock and warrants to purchase 681,275 shares of common stock was $0.1 million and $0.4 million as of March 31, 2014 and December 31, 2013, respectively. These values were determined by using the Black-Scholes option pricing model which is based on the Company’s stock price at measurement date, exercise price of this common stock warrant, risk-free interest rate and historical volatility, and are classified as a Level 2 measurement. During the three months ended March 31, 2014 and 2013, the Company recorded gains of $0.3 million and $0.2 million, respectively, to adjust the value of the common stock warrant liability to fair value.
	The fair values of accounts receivable and accounts payable approximate their respective carrying amounts. The Company’s long-term debt is carried at amortized face value which approximates fair value based on current market pricing of similar debt instruments and is categorized as a Level 2 measurement.

Related_Party_Transactions

Related Party Transactions	3 Months Ended
	Mar. 31, 2014
Related Party Transactions [Abstract]	'
Related Party Transactions	'
	(13) Related Party Transactions
	Prior to Columbia’s March 7, 2014 stock buy back from Actavis, Actavis beneficially owned approximately 11.5% of the Company’s outstanding common stock. Immediately following the closing of the stock repurchase and as of March 31, 2014, Actavis did not own any of the Company’s outstanding common stock. Columbia purchased the 1.4 million shares held by Actavis at a price of $6.08 per share, which represented a 10.75% discount to the market closing price on March 6, 2014. The total purchase price was approximately $8.5 million.
	Pursuant to its Purchase and Collaboration Agreement with Actavis, Columbia receives royalties equal to a minimum of 10% of annual net sales of CRINONE by Actavis for annual net sales up to $150 million; 15% for sales above $150 million but less than $250 million; and 20% for annual net sales of $250 million and over.
	The table below presents the transactions between the Company and Actavis during the three months ended March 31, 2014 (prior to the time Actavis ceased to be a related party) and the three months ended March 31, 2013 (in thousands):
		Three Months Ended
		March 31,
		2014		2013
	Revenues:
	Product revenues	$	167	$	—
	Royalties		714		800
	Total revenue	$	881	$	800
	As of March 31, 2014 any amounts due from Actavis are now classified as a component of accounts receivable, net on the consolidated balance sheet. At December 31, 2013 amounts due from Actavis for these sales were $0.9 million. There were no amounts due to Actavis at March 31, 2014 and December 31, 2013.

Income_Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2014
Income Tax Disclosure [Abstract]	'
Income Taxes	'
	(14) Income Taxes
	During the three months ended March 31, 2014 and 2013, Columbia recorded income tax expense of $12,000 and $3,000, respectively, representing an effective tax rate of 2.7% and 0.2%, respectively. The income tax provision for the three months ended March 31, 2014 is primarily attributable to taxable income generated in foreign jurisdictions.
	Columbia files income tax returns in the U.S. federal jurisdiction, and in various state and foreign jurisdictions. Columbia is no longer subject to U.S. federal income tax examinations by tax authorities for years before 2012. With few exceptions, Columbia is no longer subject to U.S. state tax examinations for years before 2009.

Interim_Consolidated_Financial1

Interim Consolidated Financial Statements (Policies)	3 Months Ended
	Mar. 31, 2014
Accounting Policies [Abstract]	'
Reclassifications	'
	Reclassifications
	For comparability purposes, certain prior period amounts in the consolidated financial statements have been reclassified to conform to the current period’s presentation within the consolidated statements of operations and consolidated statements of cash flows.
Basis of Presentation	'
	Basis of Presentation
	On July 26, 2013, Columbia’s Board of Directors set a ratio of 1-for-8 for its previously approved reverse stock split which took effect on August 9, 2013. The reverse stock split was approved by Columbia’s shareholders at its annual meeting of shareholders on May 1, 2013. All share and per share amounts relating to the common stock, stock options and warrants included in the interim consolidated financial information and accompanying footnotes have been retroactively adjusted for all periods presented to give effect to this reverse stock split, including reclassifying an equal amount to the reduction in par value of common stock to additional paid-in capital. The reverse stock split did not result in a retroactive adjustment to the share amounts for any of the classes of the Company’s preferred stock.
Management Estimates	'
	Management Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosures at the date of the financial statements during the reporting period. Significant estimates are used for, but are not limited to revenue recognition, sales return reserves, allowance for doubtful accounts, inventory reserve, impairment analysis of goodwill and intangibles including their useful lives, deferred tax assets, liabilities and valuation allowances, common stock warrant valuations, and fair value of stock options. On an ongoing basis, management evaluates its estimates. Actual results could differ from those estimates.
Sales Returns Reserves	'
	Except for sales to licensees, Columbia’s return policy allows product to be returned for a period beginning three months prior to the product expiration date and ending twelve months after the product expiration date. Products sold to Merck Serono and Actavis are not returnable to Columbia nor is Columbia responsible for returns to Merck Serono on international product sales. Columbia is only responsible for sales returns for CRINONE and PROCHIEVE products sold to domestic customers prior to the Actavis, Inc. (“Actavis”) transaction in July 2010, and for STRAINT sold prior to the sale of STRIANT® (testosterone buccal system) to Auxilium Pharmaceuticals LLC (“Auxilium”) in April 2011. Provisions for returns on sales to wholesalers, distributors and retail chain stores were estimated based on a percentage of sales, using such factors as historical sales information, distributor inventory levels and product prescription data, and were recorded as a reduction to sales in the same period as the related sales were recognized. Columbia evaluates its remaining provision for returns on a quarterly basis based on the rate of returns processed and adjusts the provision as necessary.

Inventories_Tables

Inventories (Tables)	3 Months Ended
	Mar. 31, 2014
Inventory Disclosure [Abstract]	'
Schedule of Inventory	'
	Inventories consist of the following (in thousands):
		March 31,		December 31,
		2014		2013
	Raw materials	$	480	$	771
	Work in process		1,273		775
	Finished goods		652		1,038
	Total	$	2,405	$	2,584

Goodwill_and_Intangible_Assets1

Goodwill and Intangible Assets (Tables)	3 Months Ended
	Mar. 31, 2014
Goodwill And Intangible Assets Disclosure [Abstract]	'
Schedule of Changes to Goodwill	'
	Changes to goodwill during the three months ended March 31, 2014 were as follows (in thousands):
		Total
	Balance – December 31, 2013	$	11,152
	Effects of foreign currency translation		99
	Balance – March 31, 2014	$	11,251
Changes to Intangible Assets	'
	Intangible assets consist of the following at March 31, 2014 and December 31, 2013 (in thousands):
		Trademark			Developed			Customer			Total
					Technology			Relationships
	Gross carrying amount—March 31, 2014	$	300		$	1,370		$	1,240		$	2,910
	Translation adjustment		16			76			69			161
	Accumulated amortization		(57	)		(155	)		(101	)		(313	)
	Balance—March 31, 2014	$	259		$	1,291		$	1,208		$	2,758
		Trademark			Developed			Customer			Total
					Technology			Relationships
	Gross carrying amount—December 31, 2013	$	300		$	1,370		$	1,240		$	2,910
	Translation adjustment		13			62			56			131
	Accumulated amortization		(36	)		(91	)		(86	)		(213	)
	Balance—December 31, 2013	$	277		$	1,341		$	1,210		$	2,828
Amortization Expense on Existing Intangible Assets for Next Five Years and Beyond	'
	Amortization expense for the three months ended March 31, 2014, was $0.1 million. There was no amortization expense for the three months ended March 31, 2013. As of March 31, 2014, amortization expense on existing intangible assets for the next five years and beyond is as follows (in thousands):
	Year ending December 31,	Total
	Remainder of 2014	$	421
	2015		540
	2016		490
	2017		389
	2018		357
	2019 and thereafter		561
	Total	$	2,758

Debt_and_Other_Contractual_Obl1

Debt and Other Contractual Obligations (Tables)	3 Months Ended
	Mar. 31, 2014
Text Block [Abstract]	'
Summary of Other Income on Obligation	'
	The amount of other income on the obligation that will be recognized provided the Company remains in compliance with the covenants will be the following (in thousands):
	Year	Total
	Remainder of 2014	$	266
	2015		599
	2016		865
	2017		799
	Total	$	2,529

Geographic_Information_and_Con1

Geographic Information and Concentrations (Tables)	3 Months Ended
	Mar. 31, 2014
Text Block [Abstract]	'
Selected Information by Geographic Area	'
	The following tables show selected information by geographic area (in thousands):
	Revenues:
		Three Months Ended
		March 31,
		2014		2013
	United States	$	2,501	$	918
	Switzerland		3,531		5,373
	Other countries		1,216		25
	Total	$	7,248	$	6,316
	Total assets:
		March 31,		December 31,
		2014		2013
	United States	$	12,766	$	20,278
	Switzerland		1,728		3,063
	United Kingdom		36,942		36,487
	Other countries		177		264
	Total	$	51,613	$	60,092
	Long-lived assets:
		March 31,		December 31,
		2014		2013
	United States	$	289	$	306
	Switzerland		28		22
	United Kingdom		13,557		12,987
	Other countries		2		—
	Total	$	13,876	$	13,315

Schedule_of_Property_and_Equip

Schedule of Property and Equipment (Tables)	3 Months Ended
	Mar. 31, 2014
Property Plant And Equipment [Abstract]	'
Schedule of Property and Equipment	'
	Property and equipment consists of the following:
		Estimated	March 31, 2014			December 31, 2013
		Useful Life	Cost			Cost
		(Years)
	Machinery and equipment	10-Mar	$	4,543		$	4,288
	Furniture and fixtures	5-Mar		1,010			1,010
	Computer equipment and software	3		184			183
	Buildings and leasehold improvements	Up to 39		9,701			9,616
	Land	Indefinite		632			627
	Construction in-process			673			104
				16,743			15,828
	Less: Accumulated depreciation			(2,958	)		(2,602	)
	Total		$	13,785		$	13,226

Sales_Returns_Reserves_Tables

Sales Returns Reserves (Tables)	3 Months Ended
	Mar. 31, 2014
Text Block [Abstract]	'
Analysis of Reserve for Sales	'
	An analysis of the reserve for sales returns at March 31, 2014 is as follows (in thousands):
		Total
	Balance — December 31, 2013	$	138
	Provision:
	Related to current period sales		—
	Related to prior period sales		—
			138
	Returns:
	Related to current period sales		—
	Related to prior period sales		(2	)
			(2	)
	Balance — March 31, 2014	$	136

Net_Income_Per_Common_Share_Ta

Net Income Per Common Share (Tables)	3 Months Ended
	Mar. 31, 2014
Earnings Per Share [Abstract]	'
Calculation of Basic and Diluted Income Per Common and Common Equivalent Share	'
	The calculation of basic and diluted income per common and common equivalent share is as follows (in thousands except for per share data):
		Three Months Ended
		March 31,
		2014			2013
	Basic net income per common share
	Net income	$	429		$	1,242
	Less: Preferred stock dividends		(7	)		(7	)
	Net income applicable to common stock	$	422		$	1,235
	Basic weighted average number of common shares outstanding		11,739			10,916
	Basic net income per common share	$	0.04		$	0.11
	Diluted net income per common share
	Net income applicable to common stock	$	422		$	1,235
	Add: Preferred stock dividends		7			7
	Less: Fair value of stock warrants for dilutive warrants		(309	)		(205	)
	Net income applicable to dilutive common stock	$	120		$	1,037
	Basic weighted average number of common shares outstanding		11,739			10,916
	Effect of dilutive securities
	Dilutive stock awards		25			15
	Dilutive preferred share conversions		—			142
			25			157
	Diluted weighted average number of common shares outstanding		11,764			11,073
	Diluted net income per common share	$	0.01		$	0.09

Accumulated_Other_Comprehensiv1

Accumulated Other Comprehensive Income (Tables)	3 Months Ended
	Mar. 31, 2014
Equity [Abstract]	'
Schedule of Accumulated Other Comprehensive Income	'
	Changes to accumulated other comprehensive income during the three months ended March 31, 2014 were as follows (in thousands):
		Translation		Accumulated Other
		Adjustment		Comprehensive
				Income
	Balance – December 31, 2013	$	1,370	$	1,370
	Current period other comprehensive income		206		206
	Balance – March 31, 2014	$	1,576	$	1,576

StockBased_Compensation_Tables

Stock-Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2014
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Schedule of Stock-Based Compensation Expense Allocation	'
	Total stock-based compensation expense was recorded to operating expenses based upon the functional responsibilities of the individuals holding the respective options as follows (in thousands):
		Three Months Ended
		March 31,
		2014			2013
	Sales and marketing	$	3		$	—
	General and administrative		161			106
	Total stock-based compensation	$	164		$	106
Assumptions Used to Weighted-Average Grant Date Fair Values of Options Granted	'
	The weighted-average grant date fair values of the options granted during the three months ended March 31, 2014 and 2013 were $4.51 and $3.52, respectively, using the following assumptions:
		Three Months Ended
		March 31,
		2014		2013
	Risk free interest rate	1.64%		0.71%-0.76%
	Expected term	4.75 years		4.75 years
	Dividend yield	—		—
	Expected volatility	81.36%		96.52%-97.02%

Related_Party_Transactions_Tab

Related Party Transactions (Tables)	3 Months Ended
	Mar. 31, 2014
Related Party Transactions [Abstract]	'
Schedule of Related Party Transactions	'
	The table below presents the transactions between the Company and Actavis during the three months ended March 31, 2014 (prior to the time Actavis ceased to be a related party) and the three months ended March 31, 2013 (in thousands):
		Three Months Ended
		March 31,
		2014		2013
	Revenues:
	Product revenues	$	167	$	—
	Royalties		714		800
	Total revenue	$	881	$	800

Interim_Consolidated_Financial2

Interim Consolidated Financial Statements - Additional Information (Detail)	0 Months Ended
	Jul. 26, 2013
Quarterly Financial Information Disclosure [Abstract]	'
Stockholders reverse stock split	'1-for-8
Stockholders reverse stock split, ratio	0.125
Stock split effective date	9-Aug-13

Inventories_Schedule_of_Invent

Inventories - Schedule of Inventory (Detail) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Inventory [Abstract]	'	'
Raw materials	$480	$771
Work in process	1,273	775
Finished goods	652	1,038
Total	$2,405	$2,584

Goodwill_and_Intangible_Assets2

Goodwill and Intangible Assets - Schedule of Changes to Goodwill (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014
Goodwill And Intangible Assets Disclosure [Abstract]	'
Beginning balance	$11,152
Effects of foreign currency translation	99
Ending balance	$11,251

Goodwill_and_Intangible_Assets3

Goodwill and Intangible Assets - Changes to Intangible Assets (Detail) (USD $)	3 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Dec. 31, 2013
Finite-Lived Intangible Assets [Line Items]	'	'
Gross carrying amount	$2,910	$2,910
Translation adjustment	161	131
Accumulated amortization	-313	-213
Balance	2,758	2,828
Trademark [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Gross carrying amount	300	300
Translation adjustment	16	13
Accumulated amortization	-57	-36
Balance	259	277
Developed Technology [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Gross carrying amount	1,370	1,370
Translation adjustment	76	62
Accumulated amortization	-155	-91
Balance	1,291	1,341
Customer Relationships [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Gross carrying amount	1,240	1,240
Translation adjustment	69	56
Accumulated amortization	-101	-86
Balance	$1,208	$1,210

Goodwill_and_Intangible_Assets4

Goodwill and Intangible Assets - Additional Information (Detail) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Intangible Liability Disclosure [Abstract]	'	'
Amortization expense	$0.10	$0

Goodwill_and_Intangible_Assets5

Goodwill and Intangible Assets - Amortization Expense on Existing Intangible Assets for Next Five Years and Beyond (Detail) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Goodwill And Intangible Assets Disclosure [Abstract]	'	'
Remainder of 2014	$421	'
2015	540	'
2016	490	'
2017	389	'
2018	357	'
2019 and thereafter	561	'
Total	$2,758	$2,828

Debt_and_Other_Contractual_Obl2

Debt and Other Contractual Obligations - Additional Information (Detail) (Molecular Profiles [Member], USD $)	1 Months Ended	3 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2013	Mar. 31, 2014
		Facilities
Debt Instrument [Line Items]	'	'
Debt assumed	$3.90	'
Number of loan facilities	'	3
Withdrawn amount	'	3.9
Owes due to foreign currency revaluation	'	4
Weighted average interest rate for the period	'	3.00%
Loan facilities repayment period	'	'15 years
Business acquisition maturity period	'	'2017-10
Loan Facility One [Member]	'	'
Debt Instrument [Line Items]	'	'
Loan repayment commencement period	'	'2013-02
Interest rate at the end of period	'	2.45%
Loan facilities bear interest rate	'	1.95%
Loan facility interest rate description	'	'Base rate plus 1.95%
Loan Facility Two [Member]	'	'
Debt Instrument [Line Items]	'	'
Loan repayment commencement period	'	'2013-10
Interest rate at the end of period	'	3.05%
Loan facilities bear interest rate	'	2.55%
Loan facility interest rate description	'	'Base rate plus 2.55%
Loan Facility Three [Member]	'	'
Debt Instrument [Line Items]	'	'
Loan repayment commencement period	'	'2013-10
Loan facilities bear interest rate	'	3.52%
Regional Growth Fund [Member]	'	'
Debt Instrument [Line Items]	'	'
Debt assumed	'	2.5
Deferred revenue	'	$2.50

Debt_and_Other_Contractual_Obl3

Debt and Other Contractual Obligations - Summary of Other Income on Obligation (Detail) (Regional Growth Fund [Member], Molecular Profiles [Member], USD $)	Mar. 31, 2014
In Thousands, unless otherwise specified
Regional Growth Fund [Member] | Molecular Profiles [Member]	'
Contractual Obligation [Line Items]	'
Remainder of 2014	$266
2015	599
2016	865
2017	799
Total	$2,529

Geographic_Information_and_Con2

Geographic Information and Concentrations - Additional Information (Detail)	3 Months Ended		12 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013
	Country	Customer	Country
	Customer
	Segment
	Operations
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'
Number of operating segments	1	'	'
Number of operational location	1	'	'
Number of countries represented greater than 10% of total revenues	0	'	0
Number of countries represented greater than 10% of total assets	0	'	0
Number of countries represented greater than 10% of total long-lived assets	0	'	0
Additional customers accounted for 10% or more of total revenues	0	0	'
Merck Serono [Member]	'	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'
Net revenues	45.00%	85.00%	'
Actavis [Member]	'	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'
Net revenues	16.00%	13.00%	'

Geographic_Information_and_Con3

Geographic Information and Concentrations - Selected Information by Geographic Area (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'
Total revenues	$7,248	$6,316	'
Total assets	51,613	'	60,092
Total Long-lived Assets	13,876	'	13,315
United States [Member]	'	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'
Total revenues	2,501	918	'
Total assets	12,766	'	20,278
Total Long-lived Assets	289	'	306
Switzerland [Member]	'	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'
Total revenues	3,531	5,373	'
Total assets	1,728	'	3,063
Total Long-lived Assets	28	'	22
Other Countries [Member]	'	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'
Total revenues	1,216	25	'
Total assets	177	'	264
Total Long-lived Assets	2	'	'
United Kingdom [Member]	'	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'
Total assets	36,942	'	36,487
Total Long-lived Assets	$13,557	'	$12,987

Property_and_Equipment_Schedul

Property and Equipment - Schedule of Property and Equipment (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Line Items]	'	'
Property plant and equipment, gross	$16,743	$15,828
Less: Accumulated depreciation	-2,958	-2,602
Total	13,785	13,226
Machinery and Equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property plant and equipment, gross	4,543	4,288
Machinery and Equipment [Member] | Minimum [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, plant and equipment useful life (in years)	'3 years	'
Machinery and Equipment [Member] | Maximum [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, plant and equipment useful life (in years)	'10 years	'
Furniture and Fixtures [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property plant and equipment, gross	1,010	1,010
Furniture and Fixtures [Member] | Minimum [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, plant and equipment useful life (in years)	'3 years	'
Furniture and Fixtures [Member] | Maximum [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, plant and equipment useful life (in years)	'5 years	'
Computer Equipment and Software [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, plant and equipment useful life (in years)	'3 years	'
Property plant and equipment, gross	184	183
Buildings and Leasehold Improvements [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property plant and equipment, gross	9,701	9,616
Land [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, plant and equipment useful life (in years)	'Indefinite	'
Property plant and equipment, gross	632	627
Construction in-Process [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property plant and equipment, gross	$673	$104
Buildings and Leasehold Improvements [Member] | Maximum [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, plant and equipment useful life (in years)	'39 years	'

Property_and_Equipment_Additio

Property and Equipment - Additional Information (Detail) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Property Plant And Equipment Useful Life And Values [Abstract]	'	'
Depreciation expense	$0.40	$0.10

Sales_Returns_Reserves_Additio

Sales Returns Reserves - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2014
Deferred Revenue Disclosure [Abstract]	'
Period of product return prior to expiration	'3 months
Period of product return after expiration	'12 months

Sales_Returns_Reserves_Analysi

Sales Returns Reserves - Analysis of Reserve for Sales (Detail) (Allowance for Sales Returns [Member], USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]	'
Balance at beginning of year	$138
Provision:	'
Sales allowances	138
Returns:	'
Sales returns	-2
Balance at end of period	136
Current Period Sales [Member]	'
Provision:	'
Sales allowances	'
Returns:	'
Sales returns	'
Prior Period Sales [Member]	'
Provision:	'
Sales allowances	'
Returns:	'
Sales returns	($2)

Net_Income_Per_Common_Share_Ca

Net Income Per Common Share - Calculation of Basic and Diluted Income Per Common and Common Equivalent Share (Detail) (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Basic net income per common share	'	'
Net income	$429	$1,242
Less: Preferred stock dividends	-7	-7
Net income applicable to common stock	422	1,235
Basic weighted average number of common shares outstanding	11,739	10,916
Basic net income per common share	$0.04	$0.11
Diluted net income per common share	'	'
Net income applicable to common stock	422	1,235
Add: Preferred stock dividends	7	7
Less: Fair value of stock warrants for dilutive warrants	-309	-205
Net income applicable to dilutive common stock	$120	$1,037
Basic weighted average number of common shares outstanding	11,739	10,916
Effect of dilutive securities	'	'
Dilutive stock awards	25	15
Dilutive preferred share conversions	'	142
Weighted average number of diluted shares outstanding adjustment	25	157
Diluted weighted average number of common shares outstanding	11,764	11,073
Diluted net income per common share	$0.01	$0.09

Net_Income_Per_Common_Share_Ad

Net Income Per Common Share - Additional Information (Detail)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Earnings Per Share [Abstract]	'	'
Antidilutive securities excluded from computation of earnings per share	1.8	1.8

Accumulated_Other_Comprehensiv2

Accumulated Other Comprehensive Income - Schedule of Accumulated Other Comprehensive Income (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014
Accumulated Other Comprehensive Income (Loss) [Line Items]	'
Balance - December 31, 2013	$1,370
Current period other comprehensive income	206
Balance - March 31, 2014	1,576
Translation Adjustment [Member]	'
Accumulated Other Comprehensive Income (Loss) [Line Items]	'
Balance - December 31, 2013	1,370
Current period other comprehensive income	206
Balance - March 31, 2014	$1,576

StockBased_Compensation_Additi

Stock-Based Compensation - Additional Information (Detail) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'	'
Share based compensation	$164,000	$106,000
Cash received from option exercised	12,000	0
Company options granted to employees, in shares	222,000	88,750
Weighted-average grand date fair values of options granted	$4.51	$3.52
Employee service share-based compensation, nonvested awards, total compensation cost not yet recognized	$1,200,000	'
Employee service share-based compensation, nonvested awards, total compensation cost not yet recognized, period for recognition	'3 years 6 months 29 days	'

StockBased_Compensation_Schedu

Stock-Based Compensation - Schedule of Stock-Based Compensation Expense Allocation (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Total stock-based compensation	$164	$106
Sales and Marketing [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Total stock-based compensation	3	'
General and Administrative [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Total stock-based compensation	$161	$106

StockBased_Compensation_Assump

Stock-Based Compensation - Assumptions Used to Weighted-Average Grant Date Fair Values of Options Granted (Detail)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Method Used [Line Items]	'	'
Risk free interest rate	1.64%	'
Expected term	'4 years 9 months	'4 years 9 months
Dividend yield	'	'
Expected volatility	81.36%	'
Minimum [Member]	'	'
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Method Used [Line Items]	'	'
Risk free interest rate	'	0.71%
Expected volatility	'	96.52%
Maximum [Member]	'	'
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Method Used [Line Items]	'	'
Risk free interest rate	'	0.76%
Expected volatility	'	97.02%

Legal_Proceedings_Additional_I

Legal Proceedings - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2014	Feb. 06, 2012
	Defendant	Complaints
Commitments And Contingencies Disclosure [Abstract]	'	'
Number of putative securities class action complaints (in complaints)	'	2
Number of officers added as defendants	3	'
Number of days to plead cognizable action	'30 days	'

Fair_Value_of_Financial_Instru1

Fair Value of Financial Instruments - Additional Information (Detail) (USD $)	1 Months Ended	3 Months Ended
In Thousands, except Share data, unless otherwise specified	Oct. 31, 2009	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013
Debt Instrument Fair Value Carrying Value [Abstract]	'	'	'	'
Common stock, shares authorized under plan, in shares	1,362,500	12,159,000	'	12,152,000
Warrants to purchase common stock, in shares	681,275	'	'	'
Derivative liability, fair value, gross liability	'	$70	'	$379
Derivative gain (loss) fair value of stock warrants	'	$309	$205	'

Related_Party_Transactions_Add

Related Party Transactions - Additional Information (Detail) (USD $)	Mar. 31, 2014	Dec. 31, 2013	Mar. 31, 2014	Mar. 07, 2014	Mar. 31, 2014
Share data in Millions, except Per Share data, unless otherwise specified			Actavis [Member]	Actavis [Member]	Actavis [Member]
					CRINONE Royalties [Member]
Related Party Transaction [Line Items]	'	'	'	'	'
Percentage of ownership of outstanding common stock	'	'	'	11.50%	'
Number of shares repurchased	'	'	1.4	'	'
Number of shares repurchased price per share	'	'	$6.08	'	'
Percentage of closing price discount on share repurchase	'	'	10.75%	'	'
Purchase price	'	'	$8,500,000	'	'
Percentage of royalties received	'	'	'	'	10.00%
Annual net sales	'	'	'	'	15.00%
Percentage of royalties received for sales between range	'	'	'	'	20.00%
Condition one for royalties received	'	'	'	'	150,000,000
Condition two for royalties received	'	'	'	'	250,000,000
Amounts due from related parties	'	900,000	'	'	'
Amounts due to Actavis	$0	$0	'	'	'

Related_Party_Transactions_Sch

Related Party Transactions - Schedule of Related Party Transactions (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Related Party Transaction [Line Items]	'	'
Product revenues	$167	'
Royalties	714	800
Collaborative Arrangement [Member]	'	'
Related Party Transaction [Line Items]	'	'
Product revenues	167	'
Royalties	714	800
Total revenue	$881	$800

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Income Tax Disclosure [Abstract]	'	'
Income tax expense	$12	$3
Effective tax rate	2.70%	0.20%